{"id":5858,"date":"2025-09-21T18:33:40","date_gmt":"2025-09-21T18:33:40","guid":{"rendered":"https:\/\/www.ahmetozyigit.com\/?page_id=5858"},"modified":"2025-09-21T19:24:25","modified_gmt":"2025-09-21T19:24:25","slug":"truecheck-kanser-taramasi","status":"publish","type":"page","link":"https:\/\/www.ahmetozyigit.com\/en\/truecheck-kanser-taramasi\/","title":{"rendered":"TrueCheck: Preventing Cancer with Liquid Biopsy"},"content":{"rendered":"
\"\"<\/figure>\n\n\n\n

TrueCheck: One Step Ahead Against Cancer with Liquid Biopsy<\/strong><\/h4>\n\n\n\n

Time is our most valuable weapon in the fight against cancer. Early diagnosis is the most critical factor in altering the course of the disease. Cancer is often a silent traveler; it can progress through the body without symptoms for years. We can compare it to an iceberg: While nothing is visible on the surface, danger can grow deeper. The TrueCheck\u2122 liquid biopsy test works like a radar, allowing us to detect this invisible iceberg underwater (Datar Cancer Genetics, 2023; Siegel et al., 2024).<\/p>\n\n\n\n

What is TrueCheck\u2122?<\/strong><\/p>\n\n\n\n

TrueCheck\u2122 yaln\u0131zca bir kan \u00f6rne\u011fi ile onlarca farkl\u0131 kanser t\u00fcr\u00fc hakk\u0131nda bilgi verebilen yenilik\u00e7i bir tarama testidir. Yakla\u015f\u0131k 70 farkl\u0131 kat\u0131 t\u00fcm\u00f6r tipini tarama kapasitesine sahiptir ve Avrupa\u2019da g\u00f6r\u00fclen kanser vakalar\u0131n\u0131n %80\u2019inden fazlas\u0131n\u0131 kapsar (Datar Cancer Genetics, 2023). Kad\u0131nlar i\u00e7in \u00f6zel olarak geli\u015ftirilmi\u015f FemmeSafe versiyonu ise meme, rahim, yumurtal\u0131k ve serviks kanserlerine odaklan\u0131r.<\/p>\n\n\n\n

Unlike traditional screenings, this test isn't specific to any specific organ. While mammography only evaluates breast cancer and colonoscopy only evaluates the intestines, TrueCheck\u2122 works like a detector that "scans" the entire body.<\/p>\n\n\n\n

How Does It Work?<\/strong><\/p>\n\n\n\n

TrueCheck\u2122 technology relies on detecting tumor cells and associated cell clusters released into the bloodstream. Normal cells are short-lived and die in a programmed manner after a certain period of time. Malignant cells, however, defy these biological rules, evade apoptosis, and survive (Shen et al., 2021).<\/p>\n\n\n\n

In the laboratory, the blood sample is placed in an epigenetically activating medium (EAM). This medium accelerates the natural death of healthy cells, while tumor cells survive. This effectively activates a screening system, leaving only cancer-related cells (Datar Cancer Genetics, 2023). In the next step, these cells are labeled using multiple immunostaining techniques, and a crime scene examination is conducted under a microscope, gathering clues about the organ or tissue they originate from. This provides an answer not only to the question of whether cancer is present but also to the question of "where should it be sought?" (Lianidou & Pantel, 2020).<\/p>\n\n\n\n

Clinical Performance<\/strong><\/p>\n\n\n\n

Yap\u0131lan klinik \u00e7al\u0131\u015fmalarda TrueCheck\u2122\u2019in t\u00fcm\u00f6rleri yakalama duyarl\u0131l\u0131\u011f\u0131 %88\u2019e kadar, \u00f6zg\u00fcll\u00fc\u011f\u00fc ise %96\u201399 aras\u0131nda bulunmu\u015ftur (Choudhury et al., 2022). Ger\u00e7ek hayat verilerinde bile bu performans korunmu\u015f, \u00f6zellikle pankreas, akci\u011fer ve yumurtal\u0131k gibi genellikle ge\u00e7 yakalanan kanserlerde olduk\u00e7a umut verici sonu\u00e7lar elde edilmi\u015ftir (Patil et al., 2023). Bu sonu\u00e7lar, testin yanl\u0131\u015f pozitif oran\u0131n\u0131n d\u00fc\u015f\u00fck oldu\u011funu ve gereksiz biyopsi veya g\u00f6r\u00fcnt\u00fclemelere yol a\u00e7ma ihtimalinin olduk\u00e7a s\u0131n\u0131rl\u0131 oldu\u011funu g\u00f6sterir.<\/p>\n\n\n\n

Who is it recommended for?<\/strong><\/p>\n\n\n\n

TrueCheck\u2122 can be used as part of a routine checkup program for healthy individuals over the age of 40. It's also logical to perform it at an earlier age for individuals with a family history of cancer, those with genetic risk factors such as BRCA1\/2, or those who have been smoking for a long time (Ghavami et al., 2022). Risk is also higher for those with a history of obesity, type 2 diabetes, chronic inflammation, or viral infections (such as HBV and HPV). This test is particularly recommended for individuals without any symptoms, as this latent stage is often when cancer is most treatable (Siegel et al., 2024).<\/p>\n\n\n\n

Advantages<\/strong><\/p>\n\n\n\n

TrueCheck\u2122 is highly convenient for patients because it doesn't require a surgical biopsy. No additional procedures are required beyond a blood draw. Its ability to detect hidden cancer cells in different parts of the body with a single test is a key advantage that distinguishes it from other screening methods (Lianidou & Pantel, 2020).<\/p>\n\n\n\n

Erken tan\u0131 konan bir kanserin tedavi ba\u015far\u0131s\u0131 dramatik bi\u00e7imde y\u00fckselir. \u00d6rne\u011fin, kolon kanserinde evre I\u2019de 5 y\u0131ll\u0131k sa\u011fkal\u0131m %90\u2019\u0131n \u00fczerindeyken, ileri evrelerde bu oran %15\u2019in alt\u0131na d\u00fc\u015fer (Siegel et al., 2024). TrueCheck\u2122 bu fark\u0131 yaratacak f\u0131rsat\u0131 sunar.<\/p>\n\n\n\n

Things to Consider<\/strong><\/p>\n\n\n\n

Her test gibi TrueCheck\u2122 de m\u00fckemmel de\u011fildir. %100 duyarl\u0131l\u0131k sa\u011flamaz, yani \u00e7ok erken evrede baz\u0131 kanserler g\u00f6zden ka\u00e7abilir. Bu nedenle mamografi, kolonoskopi gibi kan\u0131ta dayal\u0131 tarama y\u00f6ntemlerinin yerine ge\u00e7mez; onlarla birlikte kullan\u0131lmal\u0131d\u0131r (NCCN, 2023). Ayr\u0131ca pozitif sonu\u00e7 alan bir ki\u015finin kayg\u0131s\u0131 artabilir; bu y\u00fczden sonu\u00e7lar\u0131n mutlaka bir hekim taraf\u0131ndan de\u011ferlendirilmesi ve gerekirse ek g\u00f6r\u00fcnt\u00fcleme veya biyopsi ile do\u011frulanmas\u0131 gerekir.<\/p>\n\n\n\n

How Does the Process Work?<\/strong><\/p>\n\n\n\n

    \n
  1. Appointment and information: Your doctor will explain what the test is and its possible results.<\/li>\n\n\n\n
  2. Blood collection: A total of 30 ml of blood is taken into 3 tubes.<\/li>\n\n\n\n
  3. Laboratory phase: The sample is delivered to the center under special conditions, the cells are enriched and analyzed.<\/li>\n\n\n\n
  4. Result: The report will be ready in approximately 10 business days.<\/li>\n\n\n\n
  5. Interpretation: The physician evaluates the report together with other clinical findings and directs further examinations if necessary.<\/li>\n<\/ol>\n\n\n\n

    Clinical and Social Contribution<\/strong><\/p>\n\n\n\n

    Early diagnosis reduces treatment costs for advanced cancers and improves quality of life (Mariotto et al., 2020). Encouraging screening habits in society reduces the burden of cancer not only at the individual level but also at the societal level. The TrueCheck\u2122 liquid biopsy test offers a time-saving technology in the fight against cancer. When I recommend this test to my patients, my goal is to make the invisible visible and catch the disease at its earliest, most treatable stage. This is what a physician prioritizes: protecting their patients.<\/p>\n\n\n\n

    Source<\/strong><\/p>\n\n\n\n

      \n
    • Choudhury, R. et al. (2022). Clinical validation of circulating tumor-associated cell-based cancer screening. Cancer Research, 82(4): 678\u2013689.<\/li>\n\n\n\n
    • Datar Cancer Genetics. (2023). Trucheck\u2122 \u2013 Early cancer detection test. Available at: https:\/\/www.datarpgx.de\/en\/trucheck-en\/ (Accessed: 20 September 2025).<\/li>\n\n\n\n
    • Ghavami, S. et al. (2022). Liquid biopsy in oncology: Opportunities and challenges. Molecular Cancer, 21(1): 86.<\/li>\n\n\n\n
    • Lianidou, E. & Pantel, K. (2020). Liquid biopsies for cancer detection and monitoring. Clinical Chemistry, 66(1): 90\u201398.<\/li>\n\n\n\n
    • Mariotto, A. et al. (2020). Economic impact of early cancer detection. JNCI, 112(9): 857\u2013864.<\/li>\n\n\n\n
    • NCCN (2023). NCCN Guidelines: Cancer Screening. Version 2.2023.<\/li>\n\n\n\n
    • Patil, S. et al. (2023). Real-world performance of CTC-based cancer screening tests. Annals of Oncology, 34(5): 512\u2013520.<\/li>\n\n\n\n
    • Shen, Z. et al. (2021). CTC detection technologies and clinical applications. Nature Reviews Clinical Oncology, 18(9): 547\u2013567.<\/li>\n\n\n\n
    • Siegel, R.L. et al. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1): 5\u201333.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

      TrueCheck: One Step Ahead Against Cancer with Liquid Biopsy Time is our most valuable weapon in the fight against cancer. Early diagnosis is the most critical factor in changing the course of the disease. Cancer is often a silent traveler; it can progress through the body without symptoms for years. We can compare it to an iceberg: While nothing is visible on the surface, danger can grow deeper. The TrueCheck\u2122 liquid biopsy test reveals this invisible iceberg [\u2026]<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5858","page","type-page","status-publish","hentry"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/pages\/5858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/comments?post=5858"}],"version-history":[{"count":11,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/pages\/5858\/revisions"}],"predecessor-version":[{"id":5877,"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/pages\/5858\/revisions\/5877"}],"wp:attachment":[{"href":"https:\/\/www.ahmetozyigit.com\/en\/wp-json\/wp\/v2\/media?parent=5858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}